Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q3 2018 · 10-Q
Revenue$5.31M$5.31M+297.2% vs Q3 2017 Net Income-$19.20M-$19.20MN/M vs Q3 2017 EPS Diluted-$0.56-$0.56N/M vs Q3 2017 Operating Income-$22,725,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$22,929,000N/M Margins · derivedOperating margin-428.3%+1166.7 pt vs Q3 2017
Net margin-361.9%+1188.0 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 7, 2018 · 38 d after period end